Challenges in the Management of Hypertension in Older Populations
- PMID: 27815929
- DOI: 10.1007/5584_2016_149
Challenges in the Management of Hypertension in Older Populations
Abstract
The prevalence of hypertension increases with age making it a significant health concern for older persons. Aging involves a range of physiological changes such as increases in arterial stiffness, widening pulse pressure, changes in renin and aldosterone levels, decreases in renal salt excretion, declining in renal function, changes in the autonomic nervous system sensitivity and function and changes to endothelial function all of which may not only affect blood pressure but may also affect individual response to pharmacotherapy used to manage hypertension and prevent end organ damage and other complications associated with poor blood pressure control.Unlike many chronic conditions where there is limited evidence for management in older populations, there is good evidence regarding the management of hypertension in the elderly. The findings from multiple large, robust trials have provided a solid evidence-base regarding the management of hypertension in older adults, showing that reduction of blood pressure in older hypertensive populations is associated with reduced mortality and morbidity. Diuretics, agents action on the renin angiotensin system, beta blockers and calcium channel blockers have all been well studied in older populations both in view of the benefits associated with blood pressure lowering and the risks associated with associated adverse events. While all antihypertensive agents will lower blood pressure, when managing hypertension in older persons the choice of agent is dependent not only on the ability to lower blood pressure but also on the potential for harm with older persons. Understanding such potential harms in older populations is essential with older persons experiencing increased sensitivity to many of the adverse effects such as dizziness associated with the use of antihypertensive agents.Despite the wealth of evidence regarding the benefits of managing hypertension in the old and very old, a significant proportion of older individuals with hypertension have suboptimal BP control. While there is good evidence supporting blood pressure lowering in older antihypertensive agents, these have not yet been optimally translated fully into clinical guidelines and clinical practice. There appear to be considerable differences between guidelines in terms of the guidance given to clinicians. Differences in interpretation of the evidence, as well as differences in study design and populations all contribute to differences in the guideline recommendations with respect to older populations, despite the strength of the underlying scientific evidence. Differences around who is considered "old" and what BP targets and management are considered appropriate may lead to confusion among clinicians and further contribute to the evidence-practice lag.
Keywords: Aged; Antihypertensive; Drug therapy; Guidelines; Hypertension; Older; Pharmacotherapy.
Similar articles
-
The Role of Beta-Blockers in the Treatment of Hypertension.Adv Exp Med Biol. 2017;956:149-166. doi: 10.1007/5584_2016_36. Adv Exp Med Biol. 2017. PMID: 27957711 Review.
-
Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2018 Oct 23;138(17):e595-e616. doi: 10.1161/CIR.0000000000000601. Circulation. 2018. PMID: 30354656
-
The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.Trials. 2015 Dec 19;16:581. doi: 10.1186/s13063-015-1100-8. Trials. 2015. PMID: 26686682 Free PMC article.
-
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.Can J Cardiol. 2004 Jan;20(1):41-54. Can J Cardiol. 2004. PMID: 14968142
-
Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.Vasc Health Risk Manag. 2016 Nov 15;12:443-451. doi: 10.2147/VHRM.S91020. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27895487 Free PMC article. Review.
Cited by
-
Baduanjin exercise in the treatment of hypertension: A systematic review and meta-analysis.Front Cardiovasc Med. 2022 Aug 15;9:936018. doi: 10.3389/fcvm.2022.936018. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36046185 Free PMC article.
-
Nutrient deficiency patterns and all-cause and cardiovascular mortality in older adults with hypertension: a latent class analysis.BMC Public Health. 2024 Jun 10;24(1):1551. doi: 10.1186/s12889-024-19003-w. BMC Public Health. 2024. PMID: 38853236 Free PMC article.
-
LncRNA FENDRR Servers as a Possible Marker of Essential Hypertension and Regulates Human Umbilical Vein Endothelial Cells Dysfunction via miR-423-5p/Nox4 Axis.Int J Gen Med. 2022 Mar 5;15:2529-2540. doi: 10.2147/IJGM.S338147. eCollection 2022. Int J Gen Med. 2022. PMID: 35282648 Free PMC article.
-
Development, validation, and visualization of a web-based nomogram to predict 5-year mortality risk in older adults with hypertension.BMC Geriatr. 2022 May 4;22(1):392. doi: 10.1186/s12877-022-03087-3. BMC Geriatr. 2022. PMID: 35509033 Free PMC article.
-
Association between Frailty and Mortality, Falls, and Hospitalization among Patients with Hypertension: A Systematic Review and Meta-Analysis.Biomed Res Int. 2021 Jan 27;2021:2690296. doi: 10.1155/2021/2690296. eCollection 2021. Biomed Res Int. 2021. PMID: 33575325 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical